Project goals
- Synthesis and purification of recombinant protein sgp130. Sgp130 is a specific inhibitor of the pathogenic IL-6 trans-signalling pathway and does not interact with the protective immune IL-6 classic signaling pathway.
- Evaluate the anti-cancer effect of the product in an experimental model.
Project main tasks
- Design and select the sgp130 coding sequence and create cell lines that sustainably express the designed sequence.
- Procedure for synthesizing and purifying recombinant sgp130 protein.
- Determine the characteristics of recombinant sgp130 protein such as purity, interaction with IL-6 signaling pathway.
- Evaluate the anti-cancer effects of recombinant sgp130 in an experimental model.
Project impact
- Establishing and optimizing the recombinant protein synthesis process.
- The product is recombinant protein sgp130. IL-6 signaling has a central role in the protective immune response, through the classical IL-6 signaling pathway. While excessive activation of IL_6 signaling promotes malignancy through the IL-6 trans-signaling pathway. Currently available IL-6 signaling pathway inhibitors inhibit both of these pathways, leading to undesirable immunosuppressive effects. Sgp130 only inhibits pathologic IL-6 signaling but does not inhibit protective classical IL-6 signaling. This product has the potential to inhibit the cancer-promoting IL-6 signaling pathway, thus being a potential candidate for cancer treatment. Notably, compared with existing signaling pathway inhibitors, sgp130 has a superior advantage because it does not inhibit the protective immune function of IL-6 signaling, so the immunosuppressive effect can be avoided. unwanted translation.
- The product sgp130 has the potential to treat cancer and reduce unwanted effects. The success of the research is the premise for developing recombinant protein sgp130 on a larger scale. Products have the basis to be supplied to the market at competitive prices, at least for the domestic market.
